Sinopharm Medicine To Launch IPO In Hong Kong
This article was originally published in PharmAsia News
Executive Summary
Sinopharm Medicine Holding, a core subsidiary of Sinopharm, will launch its initial public offering in Hong Kong soon, according to sources who disclosed that the firm has obtained approval from the authorities and will hold a public hearing next week. The official listing, targeted for late August or early September, is expected to raise up to RMB 7 billion ($1.02 billion). However, Sinopharm Medicine Holding denied the news, but said that it would likely restructure the pharmaceutical and trade business with another Sinopharm listed subsidiary Accord Pharm after the IPO if it occurs. The move is to boost the company's poor performance in retail drugstore business, which currently only accounts for 3.6 percent of its total revenue. (Click here for more - Chinese Language)
You may also be interested in...
FDA’s New Dataset Aims To Assist Labs In Assessing Medical Device Biocompatibility
The US FDA’s device center has unveiled a new public dataset designed to assist chemistry laboratories in ensuring the robustness of chemical characterization methods used to assess the biocompatibility of medical devices.
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.